Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

被引:0
|
作者
Tang, Amber B. [1 ]
Ziaeian, Boback [2 ]
Butler, Javed [3 ,4 ]
Yancy, Clyde W. [5 ]
Fonarow, Gregg C. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Cardiol, 10833 LeConte Ave, Los Angeles, CA 90095 USA
[3] Baylor Scott & White Res Inst, Dallas, TX USA
[4] Univ Mississippi, Jackson, MS USA
[5] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
关键词
D O I
10.1001/jamacardio.2024.3023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and ParticipantsEstimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and MeasuresAll-cause mortality. ResultsOf an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving beta-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and RelevanceImprovement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
引用
收藏
页码:1154 / 1158
页数:5
相关论文
共 50 条
  • [31] Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure
    Brooksbank, Jeremy A.
    Faulkenberg, Kathleen D.
    Tang, W. H. Wilson
    Martyn, Trejeeve
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2023, 25 (05) : 93 - 110
  • [32] Beyond Guideline-Directed Medical Therapy Nonpharmacologic Management for Patients With Heart Failure
    Ilonze, Onyedika J.
    Forman, Daniel E.
    Lemond, Lisa
    Myers, Jonathan
    Hummel, Scott
    Vest, Amanda R.
    Defilippis, Ersilia M.
    Habib, Eiad
    Goodlin, Sarah J.
    JACC-HEART FAILURE, 2025, 13 (02) : 185 - 199
  • [33] Benefits of guideline-directed medical therapy to loop diuretics in management of heart failure
    Kusunose, Kenya
    Okushi, Yuichiro
    Okayama, Yoshihiro
    Zheng, Robert
    Nakai, Michikazu
    Sumita, Yoko
    Ise, Takayuki
    Yamaguchi, Koji
    Yagi, Shusuke
    Yamada, Hirotsugu
    Soeki, Takeshi
    Wakatsuki, Tetsuzo
    Sata, Masataka
    JOURNAL OF MEDICAL INVESTIGATION, 2023, 70 (1-2): : 41 - 53
  • [34] Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
    Patel, Jay
    Rassekh, Negin
    Fonarow, Gregg C.
    Deedwania, Prakash
    Sheikh, Farooq H.
    Ahmed, Ali
    Lam, Phillip H.
    DRUGS, 2023, 83 (09) : 747 - 759
  • [35] Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction
    Agarwal, Anubha
    Peters, Sanne A. E.
    Chandramouli, Chanchal
    Lam, Carolyn S. P.
    Figtree, Gemma A.
    Arnott, Clare
    CURRENT HEART FAILURE REPORTS, 2021, 18 (05) : 284 - 289
  • [36] Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure
    Tran, Richard H.
    Aldemerdash, Ahmed
    Chang, Patricia
    Sueta, Carla A.
    Kaufman, Brystana
    Asafu-adjei, Josephine
    Vardeny, Orly
    Daubert, Eliza
    Alburikan, Khalid A.
    Kucharska-Newton, Anna M.
    Stearns, Sally C.
    Rodgers, Jo E.
    PHARMACOTHERAPY, 2018, 38 (04): : 406 - 416
  • [37] Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure
    Jeremy A. Brooksbank
    Kathleen D. Faulkenberg
    W. H. Wilson Tang
    Trejeeve Martyn
    Current Treatment Options in Cardiovascular Medicine, 2023, 25 : 93 - 110
  • [38] Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction
    Jabri, Ahmad
    Alhuneafat, Laith
    Shahrori, Zaid
    Hamade, Hani
    Nasser, Farhan
    Rayyan, Abdallah
    Mhanna, Mohammed
    Al Abdouh, Ahmad
    Haddadin, Faris
    Balakumaran, Kathir
    JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2022, 14 (08): : 315 - 320
  • [39] Impact of multidisciplinary team heart failure clinic in utilization of guideline-directed medical therapy and clinical outcomes
    Chua, P. L. Ping Lik
    Sie, S. S. Tan Sie
    Malek, A. M. Abdul Muizz Bin Abdul
    Hisham, S. A. Shairyzah Ahmad
    Kiong, S. K. Glendon Lau Seng
    Chuan, H. C. Julian Tey Hock
    Chen, J. C. Lim Jian
    Zubairi, A. A. Ahmad Aiman Azri Bin Ahmad
    Bin Abd Ghani, A. R. Abdul Raqib
    Bin Ismail, Ni Norzian
    Selvaraj, K. Kamaraj
    Ramaiah, A. R. Asri Ranga Bin Abdullah
    Bin Abd Ghapar, Ak Abd Kahar
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 109 - 110
  • [40] Impact of discharge checklist on guideline-directed medical therapy and mid-term prognosis in heart failure
    Lee, Won-Seok
    Lee, Kyu-Sun
    Rismiati, Helsi
    Lee, Hae-Young
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2024, 39 (06):